China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT). The partnership, which leverages the companies’ respective expertise and successful track records in virus vector production, aims to deliver innovative solutions in the CGT field worldwide through technological synergy and resource integration.
Collaboration Details
The collaboration will utilize Eureka Bio’s EuLV system, a lentiviral vector production platform based on stable cell lines, combined with VectorBuilder’s technological innovation, full-service capabilities, and global marketing network in gene delivery. The goal is to accelerate technical upgrades and industry translation in the CGT sector. Financial terms of the partnership were not disclosed.-Fineline Info & Tech
